Daniela Patricia Ladner

Daniela Patricia Ladner

Auto-generated profile, based on publicly available information

Daniela Patricia Ladner

Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center (CTC), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2017 in Hepatology
Verified
Journal Article
Closed access
PDF file
LVLisa B. VanWagner
Lisa B. VanWagner
HNHongyan Ning
Hongyan Ning
MWMaureen Whitsett
Maureen Whitsett
JLJosh Levitsky
Josh Levitsky
SUSarah Uttal
Sarah Uttal
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones

29 December 2021 in Hepatology
Verified
Journal Article
Closed access
JLJennifer C. Lai
Jennifer C. Lai
ASAmy M. Shui
Amy M. Shui
ADAndres Duarte‐Rojo
Andres Duarte‐Rojo
DGDaniel R. Ganger
Daniel R. Ganger
RRRobert S. Rahimi
Robert S. Rahimi
FSfrom the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study
from the Multi‐Center Functional Assessment in Liver Transplantation (FrAILT) Study

15 November 2019 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
LVLisa B. VanWagner
Lisa B. VanWagner
JHJane L. Holl
Jane L. Holl
SMSamantha Montag
Samantha Montag
DGDyanna Gregory
Dyanna Gregory
SCSean Connolly
Sean Connolly
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
Data for liver transplant recipients (LTRs) regarding the benefit of care concordant with clinical practice guidelines for management of blood pressure (BP) are sparse. This paper reports on clinician adherence with BP clinical practice guideline recommendations and whether BP control is associated with mortality and cardiovascular events (CVEs) among LTRs. We conducted a longitudinal cohort study of adult LTRs who survived to hospital discharge at a large tertiary care network between 2010 and 2016. The primary exposure was a BP of <140/<90 mmHg within year 1 of LT. Among 602 LTRs (mean age 56.7 years, 64% men), 92% had hypertension and 38% had new onset hypertension. Less than 30% of LTRs achieved a BP of <140/<90 mmHg over a mean of 43.2 months. In multivariable models, adjusted for key confounders, BP control post‐LT compared with lack of control was associated with a significantly lower hazard of mortality (Hazard Ratio (HR) 0.48, 95% confidence interval (CI) 0.39, 0.87) and of CVEs (HR 0.65, 95%CI 0.43, 0.97). The association between BP control of <140/<90 mmHg with improved survival and decreased CVEs in LTRs suggests that efforts to improve clinician adherence to BP clinical practice recommendations should be intensified.

17 October 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
EGElisa J. Gordon
Elisa J. Gordon
JUJefferson J. Uriarte
Jefferson J. Uriarte
JLJungwha Lee
Jungwha Lee
RKRaymong Kang
Raymong Kang
MSMichelle Shumate
Michelle Shumate
JCJuan Carlos Caicedo
Juan Carlos Caicedo
ClinicalTrials.gov registered (retrospectively) on 9–7-17 (NCT03276390).

16 May 2018 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
EGElisa J. Gordon
Elisa J. Gordon
JLJungwha Lee
Jungwha Lee
RKRaymond H. Kang
Raymond H. Kang
JCJuan Carlos Caicedo
Juan Carlos Caicedo
JHJane L. Holl
Jane L. Holl
MSMichelle D. Shumate
Michelle D. Shumate
The shortage of organs for kidney transplantation for patients with end-stage renal disease (ESRD) is magnified in Hispanics/Latin Americans in the United States. Living donor kidney transplantation (LDKT) is the treatment of choice for ESRD. However, compared to their representation on the transplant waitlist, fewer Hispanics receive a LDKT than non-Hispanic whites. Barriers to LDKT for Hispanics include: lack of knowledge, cultural concerns, and language barriers. Few interventions have been designed to reduce LDKT disparities. This study aims to reduce Hispanic disparities in LDKT through a culturally targeted intervention. Using a prospective effectiveness-implementation hybrid design involving pre-post intervention evaluation with matched controls, we will implement a complex culturally targeted intervention at two transplant centers in Dallas, TX and Phoenix, AZ. The goal of the study is to evaluate the effect of Northwestern Medicine’s® Hispanic Kidney Transplant Program’s (HKTP) key culturally targeted components (outreach, communication, education) on Hispanic LDKT rates over five years. The main hypothesis is that exposure to the HKTP will reduce disparities by increasing the ratio of Hispanic to non-Hispanic white LDKTs and the number of Hispanic LDKTs. We will also examine other process and outcome measures including: dialysis patient outreach, education session attendance, marketing efforts, Hispanic patients added to the waitlist, Hispanic potential donors per potential recipient, and satisfaction with culturally competent care. We will use mixed methods based on the Promoting Action on Research Implementation in Health Services (revised PARIHS) and the Consolidated Framework for Implementation Research (CFIR) frameworks to formatively evaluate the fidelity and innovative adaptations to HKTP’s components at both study sites, to identify moderating factors that most affect implementation fidelity, and to identify adaptations that positively and negatively affect outcomes for patients. Our study will provide new knowledge about implementing culturally targeted interventions and their impact on reducing health disparities. Moreover, the study of a complex organizational-level intervention’s implementation over five years is rare in implementation science; as such, this study is poised to contribute new knowledge to the factors influencing how organizational-level interventions are sustained over time. (ClinicalTrials.gov registration # NCT03276390 , date of registration: 9–7-17, retrospectively registered)

21 October 2019 in Transplantation
Verified
Journal Article
Closed access
NMNikhilesh R. Mazumder
Nikhilesh R. Mazumder
KAKofi Atiemo
Kofi Atiemo
ADAmna Daud
Amna Daud
AKAbel Kho
Abel Kho
MAMichael Md Abecassis
Michael Md Abecassis
DLDaniela P. Ladner
Daniela P. Ladner
Background.: The vast majority of patients with cirrhosis have low Model for End-Stage Liver Disease–Sodium (MELD-Na) scores; however, the ability for the MELD-Na score to predict patient outcomes at low scores is unclear. Methods.: Adult patients in a multicenter, Chicago-wide database of medical records with International Classification of Disease, Ninth Edition codes of cirrhosis and without a history of hepatocellular carcinoma were included. Records were linked with the state death registry, and death certificates were manually reviewed. Deaths were classified as “liver-related,” “non-liver-related,” and “non-descript” as adjudicated by a panel comprised of a transplant surgeon, a hepatologist, and an internist. A sensitivity analysis was performed where patients with hepatocellular carcinoma were included. Results.: Among 7922 identified patients, 3999 patients had MELD-Na scores that were never higher than 15. In total, 2137 (27%) patients died during the study period with higher mortality rates for the patients in the high MELD-Na group (19.4 (41.6%) versus 4.1 (12.6%) per 100 person-y, P < 0.001). The high MELD-Na group died of a liver-related cause in 1142 out of 1632 (70%) as compared to 240 out of 505 (47.5%) deaths in the low MELD-Na group. There was no difference in the distribution of subcategory of liver-related death between low and high MELD-Na groups. Among subclassification of liver-related deaths, the most common cause of death was “Infectious” in both groups. Conclusions.: Despite persistently low MELD-Na scores, patients with cirrhosis still experience high rates of liver-related mortality.